Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Volume: 13, Issue: 8, Pages: 473 - 486
Published: Aug 1, 2016
Abstract
Inhibition of immune checkpoints using anti-programmed cell death-1 (PD-1) or anti cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibodies has revolutionized the management of patients with advanced-stage melanoma and is among the most promising treatment approaches for many other cancers. Use of CTLA-4 and PD-1 inhibitors, either as single agents, or in combination, has been approved by the US FDA for the treatment of...
Paper Details
Title
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Published Date
Aug 1, 2016
Volume
13
Issue
8
Pages
473 - 486
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.